Literature DB >> 8993992

Validation of coronary artery saphenous vein bypass graft diameter measurements using quantitative angiography.

J Lespérance1, L Campeau, J H Reiber, M Bois, I Dyrda, J Laurier, G Hudon.   

Abstract

The accepted value for reproducibility (true change) is two standard deviations (SD) of the differences between repeat measurements. It has been well established for coronary artery measurements using several different quantitative coronary angiography (QCA) systems, but it has not been well documented for saphenous vein grafts (SVG). The purpose of this study was to assess, using the Cardiovascular Measurement System (CMS), the measurement reproducibility of 24 vein grafts from 24 patients who had symptom-directed control angiography. Three equal graft segments were studied separately. Focal narrowings expressed in percent stenosis varied from 5 to 80% (mean 20.8 +/- 15.9%). The average minimum lumen diameter (MLD) was 3.07 +/- 0.81 mm and the average interpolated reference diameter (Ref. D) was 3.87 +/- 0.58 mm. We assessed the reproducibility of measurements obtained from two separate imagings of the graft in the same view but at least 20 minutes apart, near the beginning and at the end of the angiographic procedure (simulating baseline and end-trial examinations). The SD for differences in measurements (variability) was 0.183 mm for the MLD, 0.193 mm for the Ref.D, 0.184 mm for the mean diameter (Mean D) and 3.72% for the percent diameter stenosis (PDS). A reasonable true change cut-off for SVG measurements in our laboratory is > or = 0.4 mm for the minimum and mean lumen diameters, and > or = 10% for the PDS, when QCA is obtained with the QCA-CMS analytical software package.

Entities:  

Mesh:

Year:  1996        PMID: 8993992     DOI: 10.1007/bf01797743

Source DB:  PubMed          Journal:  Int J Card Imaging        ISSN: 0167-9899


  9 in total

1.  Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect.

Authors:  D H Blankenhorn; R H Selzer; W J Mack; D W Crawford; J Pogoda; P L Lee; A M Shircore; S P Azen
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

2.  Measuring progression and regression of coronary atherosclerosis in clinical trials: problems and progress.

Authors:  J Lespérance; D Waters
Journal:  Int J Card Imaging       Date:  1992

Review 3.  Quantitative computer techniques for analyzing coronary arteriograms.

Authors:  B G Brown; E L Bolson; H T Dodge
Journal:  Prog Cardiovasc Dis       Date:  1986 May-Jun       Impact factor: 8.194

4.  Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms.

Authors:  J H Reiber; P W Serruys; C J Kooijman; W Wijns; C J Slager; J J Gerbrands; J C Schuurbiers; A den Boer; P G Hugenholtz
Journal:  Circulation       Date:  1985-02       Impact factor: 29.690

Review 5.  Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis. Implications for clinical trials.

Authors:  D Waters; J Lespérance; T E Craven; G Hudon; L D Gillam
Journal:  Circulation       Date:  1993-03       Impact factor: 29.690

6.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

Authors:  D Waters; L Higginson; P Gladstone; B Kimball; M Le May; S J Boccuzzi; J Lespérance
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

7.  Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study.

Authors:  M Syvänne; M S Nieminen; M H Frick
Journal:  Int J Card Imaging       Date:  1994-12

8.  Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators.

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; J W Deckers
Journal:  Lancet       Date:  1990-05-12       Impact factor: 79.321

9.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).

Authors:  J W Jukema; A V Bruschke; A J van Boven; J H Reiber; E T Bal; A H Zwinderman; H Jansen; G J Boerma; F M van Rappard; K I Lie
Journal:  Circulation       Date:  1995-05-15       Impact factor: 29.690

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.